New imaging method for diagnosing multiple myeloma
Official title: Clinical PET Imaging Evaluation of 68Ga-NB381 Probe in Multiple Myeloma
Run by Peking University First Hospital · NCT06385652 · Data updated 2026-11-12
This study is testing a new imaging method to see if it can help doctors diagnose multiple myeloma earlier and more accurately than current methods.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Peking University First Hospital Academic / other |
| Drugs / interventions | daratumumab |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | April 1, 2024 |
| Main results expected | June 3, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | April 16, 2026 |
| Trial ID | NCT06385652 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients aged 18 to 80 who are suspected of having multiple myeloma and are scheduled for a biopsy within the next three months.
✕Probably not a fit
Patients who are pregnant or unable to understand the examination process will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on developing a novel PET imaging probe, 68Ga-NB381, which targets the CD38 biomarker overexpressed in multiple myeloma (MM) cells. By enhancing the specificity and sensitivity of imaging, this approach aims to improve early diagnosis of MM, which is often missed due to reliance on invasive bone marrow biopsies. The study will involve comprehensive assessments, including patient selection and high-precision imaging, to evaluate the effectiveness of this new imaging agent in patients suspected of having MM.
Why it matters
Potential benefit: If successful, this imaging method could lead to earlier and more accurate diagnoses of multiple myeloma, improving patient outcomes.
How similar studies have gone: While the approach of using targeted nanobodies in imaging is promising, this specific application of 68Ga-NB381 in multiple myeloma is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients suspected of multiple myeloma who are scheduled to undergo bone marrow aspiration or tissue biopsy within the next 3 months; aged between 18 and 90 years; participants must fully understand and voluntarily participate in this study, and sign an informed consent form; must be able to independently comply with the examination procedures. * Confirmed symptomatic multiple myeloma patients; aged over 18 years; participants must fully understand and voluntarily participate in this study, and sign an informed consent form; must be able to independently comply with the examination procedures. Exclusion Criteria: * Pregnant women * Individuals who cannot understand the examination process or are unable to cooperate.
Where it's running
-
Peking University First Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: TIANYAO Wang, PhD
- Email: tianyao.wang@pkufh.com
- Phone: +8613439014669
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma
In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.
-
Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma
This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.
-
SMS text check-ins to track symptoms for people with plasma cell disorders
This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.
-
Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma
This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.